Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Joshua E Reuss"'
Autor:
Jiajia Zhang, Julie R Brahmer, Patrick M Forde, Tanguy Seiwert, Valsamo Anagnostou, Samuel Rosner, Victor E Velculescu, James R White, Joshua E Reuss, Gavin Pereira, Vincent Lam, Christine Hann, Michael Hwang, Kristen Marrone, Kellie N Smith, Joseph C Murray, Jamie E Chaft, Lavanya Sivapalan, Jenna Vanliere Canzoniero, Guangfan Zhang, Zineb Belcaid, Christopher Cherry, Archana Balan, Alexandria Curry, Noushin Niknafs, Qing Kay Li, Benjamin P Levy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/da2666dd4bbf43a0ba1fac37b8c8e007
Autor:
Drew M Pardoll, Julie R Brahmer, Patrick M Forde, Jarushka Naidoo, David Jones, Taha Merghoub, Suzanne Topalian, Gary Rosner, Valsamo Anagnostou, Hok Yee Chan, Franco Verde, Daphne Wang, Matthew D Hellmann, Victor E Velculescu, James R White, Tricia R Cottrell, Joshua E Reuss, Stephen Broderick, Kellie N Smith, Marianna Zahurak, Mara Lanis, Joseph C Murray, Caroline McCarthy, Richard Battafarano, Errol Bush, Malcolm Brock, Jinny Ha, Janis Taube, Peter Illei, Ben Levy, Jamie E Chaft
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with an encouraging rate of pathologic response. Building on these results, a
Externí odkaz:
https://doaj.org/article/d4bfc22689794dbda7a5be0ad8d85c44
Autor:
Julie R Brahmer, Patrick M Forde, Jarushka Naidoo, Mizuki Nishino, David Feller-Kopman, Karthik Suresh, Joshua E Reuss, Seema Mehta Steinke, Clare Rock, Douglas B Johnson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Immune-related (IR)-pneumonitis is a rare and potentially fatal toxicity of anti-PD(L)1 immunotherapy. Expert guidelines for the diagnosis and management of IR-pneumonitis include multidisciplinary input from medical oncology, pulmonary medicine, inf
Externí odkaz:
https://doaj.org/article/05d55451c8ff4066a3ca32fd51d3accd
Autor:
Laura Schubert, Andrew Elliott, Anh T. Le, Adriana Estrada-Bernal, Robert C. Doebele, Emil Lou, Hossein Borghaei, Michael J. Demeure, Razelle Kurzrock, Joshua E. Reuss, Sai-Hong Ignatius Ou, David R. Braxton, Christian A. Thomas, Sourat Darabi, Wolfgang Michael Korn, Wafik S. El-Deiry, Stephen V. Liu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PurposeGene fusions involving receptor tyrosine kinases (RTKs) define an important class of genomic alterations with many successful targeted therapies now approved for ALK, ROS1, RET and NTRK gene fusions. Fusions involving the ERBB family of RTKs h
Externí odkaz:
https://doaj.org/article/70a0b6cd821d4f078b9efca4a60b1301
Autor:
Molly Wilgucki, DO, Vincent Yeung, MD, Grace Ho, MD, Gabriela L. Bravo Montenegro, MD, Greg Jones, Joshua E. Reuss, MD, Stephen V. Liu, MD, Chul Kim, MD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100396- (2022)
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the frontline standard in the treatment of metastatic EGFR-mutant NSCLC. Although osimertinib is effective, disease progression occurs in virtually all patients, mediated by a heterog
Externí odkaz:
https://doaj.org/article/9d3591ef52d14726b8aabbb45542a674
Autor:
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen R. Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde
Publikováno v:
Clinical Cancer Research. 29:705-710
Purpose:Neoadjuvant anti–PD-1 therapy has shown promise for resectable non–small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant nivolumab in resectable NSCLC, finding it to be safe and feasible with encouraging ma
Publikováno v:
Current Oncology Reports. 24:1829-1841
Autor:
Patrick M. Forde, Jamie E. Chaft, Julie R. Brahmer, Drew M. Pardoll, Suzanne L. Topalian, David R. Jones, Stephen R. Broderick, Peter B. Illei, Joanne Riemer, Kellie N. Smith, Valsamo Anagnostou, Janis Taube, Zhen Zeng, Jiajia Zhang, Marianna Zahurak, Joshua E. Reuss, Samuel Rosner
Purpose:Neoadjuvant anti–PD-1 therapy has shown promise for resectable non–small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant nivolumab in resectable NSCLC, finding it to be safe and feasible with encouraging ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd3254ec46489d3128c3ce00a135879d
https://doi.org/10.1158/1078-0432.c.6533117.v1
https://doi.org/10.1158/1078-0432.c.6533117.v1
Autor:
Samir N. Khleif, Richard Simon, Seema Gupta, Pooja Mehra, Osama Abu-Shawer, Ghazaleh Shoja E Razavi, Anita Giobbie-Hurder, Joshua E. Reuss, Osama E. Rahma
Supplementary Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4e4b3b8cacd81b37819f934d02376a5
https://doi.org/10.1158/1078-0432.22479575
https://doi.org/10.1158/1078-0432.22479575
Autor:
Kellie N. Smith, Hongkai Ji, Drew M. Pardoll, Patrick M. Forde, Matthew D. Hellmann, Franck Housseau, Julie R. Brahmer, Victor E. Velculescu, Janis M. Taube, Edward Gabrielson, Jarushka Naidoo, Kristen A. Marrone, David R. Jones, Jinny S. Ha, Ni Zhao, John-William Sidhom, Mohsen Abu-Akeel, Richard L. Blosser, Ada J. Tam, Joshua E. Reuss, Jamie E. Chaft, Taha Merghoub, Haidan Guo, Prerna Suri, Hok Yee Chan, Tricia R. Cottrell, Valsamo Anagnostou, Margueritta El Asmar, Justina X. Caushi, Zhicheng Ji, Jiajia Zhang
Correlative assays performed on each sample
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f66fe7e9b5f6dee2fa998cf61f1a92d
https://doi.org/10.1158/1078-0432.22478577
https://doi.org/10.1158/1078-0432.22478577